Literature DB >> 19674968

The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.

Malte Kriegs1, Tilmann Bürckstümmer2, Kyoshi Himmelsbach3, Michael Bruns4, Lars Frelin5, Gustaf Ahlén5, Matti Sällberg5, Eberhard Hildt6.   

Abstract

The role of hepatitis C virus (HCV) protein non-structural (NS) 5A in HCV-associated pathogenesis is still enigmatic. To investigate the in vivo role of NS5A for viral persistence and virus-associated pathogenesis a transgenic (Tg) mouse model was established. Mice with liver-targeted NS5A transgene expression were generated using the albumin promoter. Alterations in the hepatic immune response were determined by Western blot, infection by lymphocytic choriomeningitis virus (LCMV), and using transient NS3/4A Tg mice generated by hydrodynamic injection. Cytotoxic T lymphocyte (CTL) activity was investigated by the Cr-release assay. The stable NS5A Tg mice did not reveal signs of spontaneous liver disease. The intrahepatic immunity was disrupted in the NS5A Tg mice as determined by clearance of LCMV infection or transiently NS3/4A Tg hepatocytes in vivo. This impaired immunity was explained by a reduced induction of interferon beta, 2',5'-OAS, and PKR after LCMV infection and an impairment of the CTL-mediated elimination of NS3-expressing hepatocytes. In conclusion, these data indicate that in the present transgenic mouse model, NS5A does not cause spontaneous liver disease. However, we discovered that NS5A could impair both the innate and the adaptive immune response to promote chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19674968      PMCID: PMC2788884          DOI: 10.1074/jbc.M109.038877

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice.

Authors:  Eberhard Hildt; Barbara Munz; Gesine Saher; Kurt Reifenberg; Peter Hans Hofschneider
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

2.  In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.

Authors:  Gustaf Ahlen; Jessica Nystrom; Irmgard Pult; Lars Frelin; Catharina Hultgren; Matti Sallberg
Journal:  J Infect Dis       Date:  2005-11-04       Impact factor: 5.226

3.  Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice.

Authors:  Alex Blindenbacher; Francois H T Duong; Lukas Hunziker; Simone T D Stutvoet; Xueya Wang; Luigi Terracciano; Darius Moradpour; Hubert E Blum; Tonino Alonzi; Marco Tripodi; Nicola La Monica; Markus H Heim
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

4.  The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene.

Authors:  U Lauer; L Weiss; P H Hofschneider; A S Kekulé
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling.

Authors:  S L Tan; H Nakao; Y He; S Vijaysri; P Neddermann; B L Jacobs; B J Mayer; M G Katze
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.

Authors:  L Frelin; G Ahlén; M Alheim; O Weiland; C Barnfield; P Liljeström; M Sällberg
Journal:  Gene Ther       Date:  2004-03       Impact factor: 5.250

7.  Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.

Authors:  M Gale; B Kwieciszewski; M Dossett; H Nakao; M G Katze
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 8.  The interferon response circuit: induction and suppression by pathogenic viruses.

Authors:  Otto Haller; Georg Kochs; Friedemann Weber
Journal:  Virology       Date:  2006-01-05       Impact factor: 3.616

9.  Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain.

Authors:  Nicole Appel; Thomas Pietschmann; Ralf Bartenschlager
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade.

Authors:  Andrew Street; Andrew Macdonald; Katherine Crowder; Mark Harris
Journal:  J Biol Chem       Date:  2004-01-05       Impact factor: 5.157

View more
  19 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients.

Authors:  Angela L Rasmussen; Nicolas Tchitchek; Nathan J Susnow; Alexei L Krasnoselsky; Deborah L Diamond; Matthew M Yeh; Sean C Proll; Marcus J Korth; Kathie-Anne Walters; Sharon Lederer; Anne M Larson; Robert L Carithers; Arndt Benecke; Michael G Katze
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

3.  Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis.

Authors:  Nicholas E Martinez; Fumitaka Sato; Eiichiro Kawai; Seiichi Omura; Robert P Chervenak; Ikuo Tsunoda
Journal:  Future Virol       Date:  2012-06       Impact factor: 1.831

4.  In hepatic fibrosis, liver sinusoidal endothelial cells acquire enhanced immunogenicity.

Authors:  Michael K Connolly; Andrea S Bedrosian; Ashim Malhotra; Justin R Henning; Junaid Ibrahim; Valery Vera; Napoleon E Cieza-Rubio; Burhan U Hassan; H Leon Pachter; Steven Cohen; Alan B Frey; George Miller
Journal:  J Immunol       Date:  2010-07-16       Impact factor: 5.422

5.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

6.  The Autophagosomal SNARE Protein Syntaxin 17 Is an Essential Factor for the Hepatitis C Virus Life Cycle.

Authors:  Huimei Ren; Fabian Elgner; Bingfu Jiang; Kiyoshi Himmelsbach; Regina Medvedev; Daniela Ploen; Eberhard Hildt
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

7.  Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR.

Authors:  Lu Peng; Dongyu Liang; Wenyan Tong; Jianhua Li; Zhenghong Yuan
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

8.  A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production.

Authors:  Ronik Khachatoorian; Vaithilingaraja Arumugaswami; Piotr Ruchala; Santanu Raychaudhuri; Eden M Maloney; Edna Miao; Asim Dasgupta; Samuel W French
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

Review 9.  Dendritic cells in hepatitis C infection: can they (help) win the battle?

Authors:  Angela Dolganiuc; Gyongyi Szabo
Journal:  J Gastroenterol       Date:  2011-02-17       Impact factor: 6.772

10.  HCV NS5A and IRF9 compete for CypA binding.

Authors:  Michael Bobardt; Sam Hopkins; James Baugh; Udayan Chatterji; Felicia Hernandez; John Hiscott; Ann Sluder; Kai Lin; Philippe A Gallay
Journal:  J Hepatol       Date:  2012-08-15       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.